Transcatheter aortic valve implantation: a blueprint for evidence-based evaluation of technological innovation
- PMID: 36660805
- DOI: 10.1093/eurheartj/ehac635
Transcatheter aortic valve implantation: a blueprint for evidence-based evaluation of technological innovation
Conflict of interest statement
Conflict of interest: T.P. reports research grants to the institution from Biotronik, Boston Scientific, and Edwards Lifesciences; and speaker fees/consultancy from Biotronik, Boston Scientific, Medtronic, Abbott, and HighLife SAS. G.C.M.S. reports no conflicts of interest. S.W. reports research, travel, or educational grants to the institution from Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, CardioValve, Corflow Therapeutics, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Janssen-Cilag, Johnson & Johnson, Medicure, Medtronic, Merck Sharp & Dohm, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Sanofi-Aventis, Servier, Sinomed, Terumo, Vifor, and V-Wave; and serves as advisory board member and/or member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, V-Wave, and Xeltis with payments to the institution but no personal payments. He is also a member of the steering/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration.
Comment on
-
Transcatheter versus surgical aortic valve replacement in lower-risk and higher-risk patients: a meta-analysis of randomized trials.Eur Heart J. 2023 Mar 7;44(10):836-852. doi: 10.1093/eurheartj/ehac642. Eur Heart J. 2023. PMID: 36660821
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
